Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bavituximab plus pembrolizumab in advanced gastric or gastroesophageal cancer
2019-000949-13Phase 2Unknown
- Sponsor
- OncXerna Therapeutics
- Start
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bavituximab and pembrolizumab in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by OncXerna Therapeutics. Primary endpoint: Primary antitumor activity and clinical benefit. Status: unknown.
02
Drugs
bavituximabpembrolizumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2019-000949-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000949-13.